Published in Blood on March 01, 2008
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
TRIM proteins and cancer. Nat Rev Cancer (2011) 2.84
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 2.66
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2008) 2.54
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2009) 2.34
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol (2009) 2.27
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
Arsenic trioxide - An old drug rediscovered. Blood Rev (2010) 1.49
Concern Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein. PLoS One (2014) 1.44
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood (2011) 1.41
Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med (2010) 1.39
Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. Cancer Cell (2017) 1.38
Metabolomics coupled with proteomics advancing drug discovery toward more agile development of targeted combination therapies. Mol Cell Proteomics (2013) 1.34
Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J (2010) 1.32
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A (2009) 1.32
Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther (2009) 1.27
Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J (2015) 1.27
Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One (2012) 1.21
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
Arsenic exposure and the induction of human cancers. J Toxicol (2011) 1.16
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med (2013) 1.15
Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol (2012) 1.15
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11
Arsenic(III) species inhibit oxidative protein folding in vitro. Biochemistry (2009) 1.11
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol (2009) 1.11
Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol Cancer (2011) 1.10
Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res (2012) 1.10
Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge. J Virol (2011) 1.08
Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica (2011) 1.08
Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. Mediterr J Hematol Infect Dis (2011) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell (2010) 1.07
Topoisomerase II and leukemia. Ann N Y Acad Sci (2014) 1.04
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl (2009) 1.04
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood (2014) 1.03
Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation. Mol Cell Biol (2013) 0.99
Extramedullary disease in acute promyelocytic leukemia: two-in-one disease. Mediterr J Hematol Infect Dis (2011) 0.98
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. J Biol Chem (2013) 0.97
Differentiation therapy for IDH1/2 mutant malignancies. Cell Res (2013) 0.97
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell (2016) 0.96
Regulation of Cellular Identity in Cancer. Dev Cell (2015) 0.96
Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis (2011) 0.95
E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol (2011) 0.95
Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem (2009) 0.95
Induction of metallothionein I by arsenic via metal-activated transcription factor 1: critical role of C-terminal cysteine residues in arsenic sensing. J Biol Chem (2009) 0.95
Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta (2014) 0.94
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol (2014) 0.93
Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol Exp Ther (2009) 0.93
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics (2013) 0.93
Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Exp Cell Res (2014) 0.93
Multiple cytochrome P-450 genes are concomitantly regulated by vitamin A under steady-state conditions and by retinoic acid during hepatic first-pass metabolism. Physiol Genomics (2010) 0.93
The role of PML ubiquitination in human malignancies. J Biomed Sci (2012) 0.93
MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood (2011) 0.93
Ras and Raf pathways in epidermis development and carcinogenesis. Br J Cancer (2010) 0.93
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood (2009) 0.92
Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res (2009) 0.92
Agonist antibody that induces human malignant cells to kill one another. Proc Natl Acad Sci U S A (2015) 0.92
Cancerous stem cells: deviant stem cells with cancer-causing misbehavior. Stem Cell Res Ther (2010) 0.91
Transcriptional repression of CDKN2D by PML/RARα contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells. Cell Death Dis (2014) 0.90
PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res (2015) 0.90
Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res (2014) 0.90
Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells. Int J Oncol (2011) 0.89
Genome-wide functions of PML-RARα in acute promyelocytic leukaemia. Br J Cancer (2011) 0.89
Redox platforms in cancer drug discovery and development. Curr Opin Chem Biol (2010) 0.89
Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. J Nutr (2016) 0.88
Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells. Acta Pharmacol Sin (2010) 0.88
ZBTB16-RARα variant of acute promyelocytic leukemia with tuberculosis: a case report and review of literature. Korean J Hematol (2012) 0.88
Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol (2011) 0.88
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica (2011) 0.88
Quantitative implementation of the endogenous molecular-cellular network hypothesis in hepatocellular carcinoma. Interface Focus (2014) 0.88
Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. World J Radiol (2014) 0.88
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia (2015) 0.87
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell (2016) 0.87
C/EBPα: critical at the origin of leukemic transformation. J Exp Med (2014) 0.87
Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis (2013) 0.87
Differentiation therapy of acute myeloid leukemia. Cancers (Basel) (2011) 0.87
Targeting Transcription Factors in Cancer. Trends Cancer (2015) 0.86
Study designs and statistical analyses for biomarker research. Sensors (Basel) (2012) 0.86
Arsenic toxicity to Saccharomyces cerevisiae is a consequence of inhibition of the TORC1 kinase combined with a chronic stress response. Mol Biol Cell (2008) 0.86
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6. PLoS One (2012) 0.86
Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination. J Cell Biochem (2012) 0.86
Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome. J Biol Chem (2010) 0.86
The significance of low PU.1 expression in patients with acute promyelocytic leukemia. J Hematol Oncol (2012) 0.86
Thyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review). Oncol Rep (2014) 0.86
Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J (2015) 0.85
Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients. Korean J Hematol (2011) 0.85
ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells. J Cell Physiol (2014) 0.85
Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins. Biomed Res Int (2015) 0.85
Modulation of PML protein expression regulates JCV infection. Virology (2009) 0.84
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach. Clin Cancer Res (2014) 0.84
MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS One (2013) 0.84
The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer (2016) 0.84
Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med (2012) 0.83
Effector caspases and leukemia. Int J Cell Biol (2011) 0.83
Clinical proteomics of myeloid leukemia. Genome Med (2010) 0.82
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
A human genome diversity cell line panel. Science (2002) 14.11
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet (2011) 6.98
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature (2003) 5.04
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (2010) 4.52
Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol (2003) 3.86
Systems medicine: the future of medical genomics and healthcare. Genome Med (2009) 3.85
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood (2011) 3.41
Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Med (2006) 2.99
The cdx genes and retinoic acid control the positioning and segmentation of the zebrafish pronephros. PLoS Genet (2007) 2.85
Construction and analysis of a human-chimpanzee comparative clone map. Science (2002) 2.83
Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem (2005) 2.68
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 2.66
Comparative and functional genomic analyses of the pathogenicity of phytopathogen Xanthomonas campestris pv. campestris. Genome Res (2005) 2.65
Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci U S A (2002) 2.60
Adaptive genic evolution in the Drosophila genomes. Proc Natl Acad Sci U S A (2007) 2.56
Rig-I-/- mice develop colitis associated with downregulation of G alpha i2. Cell Res (2007) 2.49
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2009) 2.34
New perspectives on host-parasite interplay by comparative transcriptomic and proteomic analyses of Schistosoma japonicum. PLoS Pathog (2006) 2.12
Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A (2008) 2.10
Transcriptional regulation of adipogenesis by KLF4. Cell Metab (2008) 2.07
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A (2005) 2.03
Evolutionary and biomedical implications of a Schistosoma japonicum complementary DNA resource. Nat Genet (2003) 2.01
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet (2002) 2.00
How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer (2002) 1.93
A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet (2011) 1.92
Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med (2011) 1.78
PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell (2010) 1.75
Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol (2005) 1.73
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A (2005) 1.67
Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab (2007) 1.63
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood (2007) 1.59
Foreword: from the TRANSCRIPTOME conferences to the SYSTEMOSCOPE international consortium. C R Biol (2004) 1.58
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood (2008) 1.50
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A (2013) 1.49
Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem (2005) 1.46
Donor-acceptor biomorphs from the ionic self-assembly of porphyrins. J Am Chem Soc (2010) 1.42
NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res (2006) 1.42
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood (2011) 1.41
Collective dipole oscillations of a spin-orbit coupled Bose-Einstein condensate. Phys Rev Lett (2012) 1.37
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2011) 1.36
Sub-10 nm thick microporous membranes made by plasma-defined atomic layer deposition of a bridged silsesquioxane precursor. J Am Chem Soc (2007) 1.35
Schistosoma genomics: new perspectives on schistosome biology and host-parasite interaction. Annu Rev Genomics Hum Genet (2009) 1.35
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A (2009) 1.32
Hematopoietic gene expression profile in zebrafish kidney marrow. Proc Natl Acad Sci U S A (2004) 1.31
Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol (2013) 1.31
Genome-wide survey and developmental expression mapping of zebrafish SET domain-containing genes. PLoS One (2008) 1.29
The genome of the hydatid tapeworm Echinococcus granulosus. Nat Genet (2013) 1.29
RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A (2006) 1.28
Curing APL through PML/RARA degradation by As2O3. Trends Mol Med (2011) 1.27
Disruption of palladin results in neural tube closure defects in mice. Mol Cell Neurosci (2005) 1.26
Cell-directed assembly of lipid-silica nanostructures providing extended cell viability. Science (2006) 1.24
Crystal structure of the TAO2 kinase domain: activation and specificity of a Ste20p MAP3K. Structure (2004) 1.21
In vivo interstitial migration of primitive macrophages mediated by JNK-matrix metalloproteinase 13 signaling in response to acute injury. J Immunol (2008) 1.19
IRF-9/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1. Cancer Res (2009) 1.18
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci (2007) 1.17
Disruption of palladin leads to defects in definitive erythropoiesis by interfering with erythroblastic island formation in mouse fetal liver. Blood (2007) 1.15
Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling. Proc Natl Acad Sci U S A (2010) 1.11
An essential role for RIG-I in toll-like receptor-stimulated phagocytosis. Cell Host Microbe (2009) 1.11
Palladin regulates cell and extracellular matrix interaction through maintaining normal actin cytoskeleton architecture and stabilizing beta1-integrin. J Cell Biochem (2007) 1.09
Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood (2005) 1.07
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2010) 1.07
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med (2012) 1.04
Localization of fatty acyl and double bond positions in phosphatidylcholines using a dual stage CID fragmentation coupled with ion mobility mass spectrometry. J Am Soc Mass Spectrom (2011) 1.03
RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci U S A (2011) 1.03
Structural shifts of gut microbiota as surrogate endpoints for monitoring host health changes induced by carcinogen exposure. FEMS Microbiol Ecol (2010) 1.03
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One (2009) 1.02
DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A (2014) 1.02
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood (2004) 1.01
siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res (2011) 1.01
Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics (2004) 1.00
Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy. Cancer Biol Ther (2003) 1.00
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res (2003) 0.99
Arsenic in cancer therapy. Anticancer Drugs (2005) 0.98
DNA methyltransferases in hematologic malignancies. Semin Hematol (2013) 0.98
Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood (2002) 0.98
Trans-repressive effect of NUP98-PMX1 on PMX1-regulated c-FOS gene through recruitment of histone deacetylase 1 by FG repeats. Cancer Res (2006) 0.97
The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia (2008) 0.97
Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med (2005) 0.97
Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells. Proc Natl Acad Sci U S A (2013) 0.96
Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves' disease. Hum Mol Genet (2009) 0.96
Rapid diagnosis and prognosis of de novo acute myeloid leukemia by serum metabonomic analysis. J Proteome Res (2013) 0.96
Makorin-2 is a neurogenesis inhibitor downstream of phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signal. J Biol Chem (2008) 0.95
Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum Mol Genet (2013) 0.95
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood (2008) 0.95
RIG-I plays a critical role in negatively regulating granulocytic proliferation. Proc Natl Acad Sci U S A (2008) 0.95
Setdb2 restricts dorsal organizer territory and regulates left-right asymmetry through suppressing fgf8 activity. Proc Natl Acad Sci U S A (2010) 0.95
Experimental validation and complexity of miRNA-mRNA target interaction during zebrafish primitive erythropoiesis. Biochem Biophys Res Commun (2009) 0.94
An evolutionarily conserved PTEN-C/EBPalpha-CTNNA1 axis controls myeloid development and transformation. Blood (2010) 0.94
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci U S A (2012) 0.93
Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. Am J Hum Genet (2009) 0.93